Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

Université Laval

$17,500.00

Public versus Private Drug Insurance and Degree of Severity of Psoriasis in Patients with Prescribed Biologics

EF 2019-20

Résumé
"Psoriasis is a chronic inflammatory disease that can affect people of all ages. It can occur in almost any body part, but most frequently involves the elbows, knees, and scalp, followed by the hands, feet, nails, and trunk. The disease can cause significant discomfort and psychological distress. One in five patients with psoriasis presents with sore joints, which can be a manifestation of psoriatic arthritis.Fortunately, several drugs are very effective for the treatment of moderate to severe psoriasis. However, some of these drugs, which are called ""biotherapies"" or ""biological drugs"" are very expensive. They can be prescribed by a dermatologist (a doctor specialized in skin diseases) to treat chronic severe psoriasis. In the province of Quebec, people who do not have access to a private plan can still take advantage of the Public Prescription Drug Insurance Plan to receive appropriate treatment and care.To this day, we don't know if patients insured under the Public Prescription Drug Insurance Plan in Quebec have similar characteristics to those with a private plan. In other words, do patients covered by the public plan have more severe psoriasis? Do they respond differently to the drugs they receive to treat their skin disease? Is the delay between the drug prescription and initiation longer? Our goal is to improve access to biotherapy treatments for patients with psoriasis. To do this, we believe it is necessary to better understand the factors that contribute to obtaining a biological agent."
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
428953
Name
Mainville Laurence
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Public versus Private Drug Insurance and Degree of Severity of Psoriasis in Patients with Prescribed Biologics
Programtype2
Studentship Programs
Orgnameinp2
Université Laval
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Access To Biotherapy; Biologics; Degree Of Severity Of Psoriasis; Dlqi; Drug Insurance Plan; Pasi; Psoriasis
Abstract
"Psoriasis is a chronic inflammatory disease that can affect people of all ages. It can occur in almost any body part, but most frequently involves the elbows, knees, and scalp, followed by the hands, feet, nails, and trunk. The disease can cause significant discomfort and psychological distress. One in five patients with psoriasis presents with sore joints, which can be a manifestation of psoriatic arthritis.Fortunately, several drugs are very effective for the treatment of moderate to severe psoriasis. However, some of these drugs, which are called ""biotherapies"" or ""biological drugs"" are very expensive. They can be prescribed by a dermatologist (a doctor specialized in skin diseases) to treat chronic severe psoriasis. In the province of Quebec, people who do not have access to a private plan can still take advantage of the Public Prescription Drug Insurance Plan to receive appropriate treatment and care.To this day, we don't know if patients insured under the Public Prescription Drug Insurance Plan in Quebec have similar characteristics to those with a private plan. In other words, do patients covered by the public plan have more severe psoriasis? Do they respond differently to the drugs they receive to treat their skin disease? Is the delay between the drug prescription and initiation longer? Our goal is to improve access to biotherapy treatments for patients with psoriasis. To do this, we believe it is necessary to better understand the factors that contribute to obtaining a biological agent."
Competitiondate
201912
Approvedterm2
1 yr 0 mth
Pinamesdelim
Mainville, Laurence
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~